Skip to main content
. 2019 Dec 18;38:497. doi: 10.1186/s13046-019-1470-y

Fig. 7.

Fig. 7

Low expression of miR-141 correlates with worse clinical outcome in pancreatic cancer patients. a and b Expression of miR-141 in pancreatic cancer based on GEO datasets. c Survival analysis of miR-141 based on the TCGA dataset. d Survival curves of IGF2BP2high&miR-141low, IGF2BP2high&miR-141high, IGF2BP2low&miR-141low and IGF2BP2low& miR-141high groups. The median survival times for each group were 16.36 months, 16.79 months, 22.83 months and undefined, respectively. e Illustration of overexpression of IGF2BP2 by multiple mechanisms activates PI3K-Akt signaling in pancreatic cancer cells. U6 served as an internal reference. Data are presented as the mean ± SD of at least three independent measurements. *P < 0.05, **P < 0.01, and ***P < 0.001. P < 0.05 was considered statistically significant